Table 4.
Comparison of absolute risk of CIN2+ based on HPV genotypes detected by the Aptima HPV-GT and cobas HPV assays when testing SurePath specimens.
| HPV result | %Absolute risk of CIN2+(95% CI) | Relative Risk (95% CI) | |
|---|---|---|---|
| Positive for 16,18/45 or 16,18 | Aptima assays | 32.1 (26.9–37.8) | vs HPV negative: 19.3 (10.7–34.7) |
| vs other HR HPV: 2.5 (1.8–3.4) | |||
| Cobas HPV Test | 31.0 (26.1–36.4) | vs HPV negative: 23.0 (11.8–44.9) | |
| vs other HR HPV: 2.6 (1.9–3.6) | |||
| Positive for other high risk typesa,b | Aptima assays | 13.1 (9.8–17.2) | vs HPV negative: 7.9 (4.2–14.7) |
| Cobas HPV Test | 11.8 (8.9–15.4) | Vs HPV negative: 8.8 (4.3–17.7) | |
| Negative for oncogenic types | AHPV assay | 1.7 1.0–2.9) | N/A |
| Cobas HPV Test | 1.3 0.7–2.5) | N/A |
CIN 2+=High grade cervical intraepithelial neoplasia grade 2 or worse.
a
Other high risk HPV types detected by Aptima HPV assay: 31, 33, 35, 39, 51, 52, 56, 58, 59, 66, and 68.
b
Other high risk HPV types detected by cobas HPV test: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.